Adaptimmune Therapeutics plc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ADAP Nasdaq 2836 www.adaptimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adaptimmune Therapeutics plc

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS) - Jan 13th, 2025 1:00 pm
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK - Dec 19th, 2024 12:30 pm
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel) - Dec 2nd, 2024 9:00 pm
Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Nov 16th, 2024 12:19 pm
Halozyme bids for Evotec; BeiGene gets a new name - Nov 15th, 2024 10:00 am
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints - Nov 14th, 2024 4:55 pm
ADAP 3Q24 Earnings Review: Streamlining the Platform; Profitability Inflection Point in 2027 - Nov 14th, 2024 9:15 am
Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ... - Nov 14th, 2024 7:15 am
Adaptimmune Reports Q3 2024 Financial and Business Updates - Nov 13th, 2024 9:05 pm
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial - Nov 13th, 2024 2:00 pm
Adaptimmune to Participate in Scientific and Medical Conferences this November and December - Nov 5th, 2024 2:19 pm
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024 - Oct 31st, 2024 9:20 pm
OTC Markets Hosts Virtual Investor Presentation with Adrian Rawcliffe, CEO of Adaptimmune Therapeutics, and Michael Kim, Senior Analyst at Zacks SCR - Oct 10th, 2024 2:29 pm
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutions - Sep 25th, 2024 10:19 am
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Sep 20th, 2024 12:35 pm
Life Sciences Virtual Investor Forum Agenda Announced for September 19th - Sep 16th, 2024 4:07 pm
Adaptimmune to Participate in Two Bank Conferences this September - Aug 28th, 2024 12:00 pm
Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years ago - Aug 15th, 2024 11:35 am
ADAP: 2Q24 Earnings Review: Tecelra FDA Approval + Capital Reload - Aug 12th, 2024 12:47 pm
Adaptimmune Reports Q2 2024 Financial and Business Updates - Aug 12th, 2024 11:00 am